Ten biopharmaceuticals gained marketing authorization in the US or EU in 2008, although only four were new approvals.
Oct 1, 2009
By:Gary Walsh, PhD
Ten biopharmaceuticals gained marketing authorization in the US or EU in 2008, although only four were new approvals.
 |
More than 70% of the products were produced in mammalian cells.
Oct 1, 2008
By:Gary Walsh, PhD
The year 2007 witnessed the approval of fifteen biopharmaceuticals in the United States and European Union.
|
Apr 1, 2008
By:Gary Walsh, PhD
The book is a useful, comprehensive, and truly an excellent reference source of biopharmaceutical information.
|
 | An overall increasing proportion of future product approvals will be engineered in some way, either directly or indirectly.
Nov 1, 2007
By:Gary Walsh, PhD
An overall increasing proportion of future product approvals will be engineered in some way, either directly or indirectly.
|
 | Thirteen biopharmaceuticals gained marketing authorization
Sep 1, 2007
By:Gary Walsh, PhD
There were notable approvals in nonparenteral delivery systems and biosimiliars in 2006.
|
Aug 1, 2006
By:Gary Walsh, PhD
In 2005, 10 biopharma- ceuticals gained marketing approval in the US or Europe, although only five of them were genuinely new molecular entities.
|
Twelve biopharmaceuticals gained marketing approval in the US and EU in 2004. Antibody-based products represented the single largest product category.
May 1, 2005
By:Gary Walsh, PhD
Cancer remains the primary indication (three products), again mirroring recent approval trends.
|
Antibody-mediated therapy is based upon the high binding specificity exhibited by antibodies for the antigen against which they are produced.
Dec 1, 2004
By:Gary Walsh, PhD
As of late 2004, 26 modern antibody-based therapeutic agents have been approved in the European Union and the US. Some 500 such products are currently in development, ensuring that the number of approved antibody-based products will increase substantially over the coming years.
|
| 
